Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer, Premier Biosoft, and Artel

Premium
PerkinElmer this week said it has launched the Geliance family of gel imaging products. Geliance offers optical performance, easy-to-use hardware and software to customers who need fluorescence and chemiluminescence imaging solutions, the company said in a statement. The Geliance 200 is designed for 1D fluorescence imaging, the Geliance 600 is designed for chemiluminescence imaging.
 
PerkinElmer also announced the release of its PhotoKinesis accessory to the UltraVIEW Live Cell Imaging System for fluorescence recovery after photobleaching, and the Spotlight 400 FT-IR imaging system, which enables laboratories to run more samples. The system provides faster data collection and longer unattended operating time, the company said.
 

 
Premier Biosoft this week launched SimGlycan, a tool to predict glycan structure by matching the experimental mass spec profile with the company’s database of theoretical fragmentation of 7,000 glycans.
 
Premier said that each structure is scored to help researchers closely match experimental data. Other information such as glycan class, reaction, pathway, and enzyme is also made available.
 

 
Artel will be launching its Liquid Handler Performance Verification service in January at Lab Automation 2007 in Palm Springs, Calif. LHPV will give laboratories third-party, documented assessment of the accuracy and precision of their equipment, the company said.
 

The new service will provide performance results traceable to national standards, the company said, and performances will be checkable for serial dilution dispensing and delivery of non-aqueous reagents. All makes and models of liquid handlers, from single to 384-channel devices, will be verifiable.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.